NCT05307705
See how this trial matches your record
Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Mayo Clinic of Scottsdale
Scottsdale, Arizona
Cancer Research SA
Adelaide, Australia
Peter Maccallum Cancer Institute Erb
East Melbourne, Australia
St Vincent's Hospital
Sydney, Australia
Institut Jules Bordet
Anderlecht, Belgium